Trials / Unknown
UnknownNCT05815693
Cognitive-behavioral Therapy for Mental Disorder in COVID-19 Survivors
Evaluate the Effectiveness for Long-term Consequences of COVID-19 of Mindfulness-based Stress Reduction (MBSR)
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 140 (estimated)
- Sponsor
- Azienda Socio Sanitaria Territoriale di Lecco · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The consequences of the Intensive Care Unit and the Covid-19 disease are still uncertain. However, many studies are bringing out often psychological and dramatic consequences for many COVID-survivor patients. Among the ex-covid patients discharged from our Intensive Care Unit and with at least one covid-related psychological consequence, we want to evaluate the effectiveness for long-term consequences of COVID-19 of mindfulness-based stress reduction (MBSR) or usual care.
Detailed description
Randomized controlled clinical study. All patients who survived COVID-19 and discharged from the intensive care unit of the Lecco hospital will be enrolled if present: chronic pain, anxiety, depression and/or insomnia in pharmacological therapy A group of patients will be observed during 12 months and evaluated with rating scales for chronic pain, anxiety, depression and insomnia. The second (experimental) group will receive psychotherapy (mindfulness-based stress reduction and cognitive behavioral therapy) in addition to the pharmacological therapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | mindfulness-based stress reduction (MBSR) and cognitive behavioral therapy (CBT) | Patients with long-term consequences of COVID-19 (Chronic pain, anxiety, depression or insomnia) enrolled and randomly assigned to receive MBSR (n = 63), or usual care (n = 62). MBSR (training in mindfulness meditation and yoga) were delivered in 12 months with 2-hour groups each 2 months. Usual care included anything care participants received such as drug therapy. |
Timeline
- Start date
- 2023-04-13
- Primary completion
- 2023-11-30
- Completion
- 2023-11-30
- First posted
- 2023-04-18
- Last updated
- 2023-06-29
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT05815693. Inclusion in this directory is not an endorsement.